Metasignatures identify two major subtypes of breast cancer

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 3, 2013, Pages

  Duan, Q ^a   Kou, Y ^a   Clark, N R ^a   Gordonov, S ^a,b   Ma'Ayan, A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HISTONE; TRANSCRIPTION FACTOR;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CELL LINE; CONTROLLED STUDY; DRUG RESPONSE; GENE CLUSTER; GENE EXPRESSION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UPREGULATION;

EID: 84880542781     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.11     Document Type: Article

References (26)

1. Korde, L.A. et al. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Res. Treat. 119, 685-699 (2010).
2. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
3. Stephens, P.J. et al.; Oslo Breast Cancer Consortium (OSBREAC). The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 (2012).
4. Gray, J. & Druker, B. Genomics: the breast cancer landscape. Nature 486, 328-329 (2012).
5. Perou, C.M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
6. van 't Veer, L.J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
7. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 98, 10869-10874 (2001). (Pubitemid 32878711)
8. Malo, T.L., Lipkus, I., Wilson, T., Han, H.S., Acs, G. & Vadaparampil, S.T. Treatment choices based on OncotypeDx in the breast oncology care setting. J. Cancer Epidemiol. 2012, 941495 (2012).
9. Wang, Y. et al. Gene-expression profiles to predict distant metastasis of lymph-nodenegative primary breast cancer. Lancet 365, 671-679 (2005). (Pubitemid 40260888)
10. Cardoso, F., Van't Veer, L., Rutgers, E., Loi, S., Mook, S. & Piccart-Gebhart, M.J. Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol. 26, 729-735 (2008). (Pubitemid 351264385)
11. Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 100, 8418-8423 (2003). (Pubitemid 36842560)
12. Paik, S. et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004). (Pubitemid 40051905)
13. Galanina, N., Bossuyt, V. & Harris, L.N. Molecular predictors of response to therapy for breast cancer. Cancer J. 17, 96-103 (2011).
14. Gunter, C. Cancer genomics: constructing a 'cancerpaedia'. Nat. Rev. Genet. 13, 300 (2012).
15. Heiser, L.M. et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl. Acad. Sci. U.S.A. 109, 2724-2729 (2012).
16. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
17. Lachmann, A., Xu, H., Krishnan, J., Berger, S.I., Mazloom, A.R. & Ma'ayan, A. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics 26, 2438-2444 (2010).
18. Bernstein, B.E. et al. The NIH roadmap epigenomics mapping consortium. Nat. Biotechnol. 28, 1045-1048 (2010).
19. Kao, K.J., Chang, K.M., Hsu, H.C. & Huang, A.T. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11, 143 (2011).
20. Young, M.D. et al. ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity. Nucleic Acids Res. 39, 7415-7427 (2011).
21. Balasubramanian, D. et al. H3K4me3 inversely correlates with DNA methylation at a large class of non-CpG-island-containing start sites. Genome Med. 4, 47 (2012).
22. Wei, Y. et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol. Carcinog. 47, 701-706 (2008).
23. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006). (Pubitemid 44497995)
24. Jenkins, S.L. & Ma'ayan, A. Systems pharmacology meets predictive, preventive, personalized and participatory medicine. Pharmacogenomics 14, 119-122 (2013).
25. Vaidyanathan, G. Redefining clinical trials: the age of personalized medicine. Cell 148, 1079-1080 (2012).
26. Zang, C., Schones, D.E., Zeng, C., Cui, K., Zhao, K. & Peng, W. A clustering approach for identification of enriched domains from histone modification ChIP-Seq data. Bioinformatics 25, 1952-1958 (2009).